Skip to content
News Archive


News prior to 2022.



Press Releases (Pre 2022)

DEC 9, 2021
Abpro Reports Its ABP 310 COVID Antibody Retains Neutralization Activity Against the SARS-CoV-2 Omicron Variant
Read More →
MAY 4, 2021
Abpro Announces Presentation and Data at the 2021 Annual Association for Research in Vision and Ophthalmology of ABP201 for the Treatment of Wet Age-related Macular Degeneration
Read More →
FEB 2, 2021
Abpro Announces Positive Phase 1 Results Demonstrating A Favorable Safety and Pharmacokinetic Profile of ABP 300, A Neutralizing Antibody Therapeutic for the Treatment of COVID-19
Read More →
DEC 16, 2020
Abpro Announces Initiation of Phase 2/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19
Read More →
NOV 25, 2020
Abpro Expands Scientific Advisory Board with the Addition of Infectious Disease Leaders
Read More →
NOV 16, 2020
Abpro Announces Peer-Reviewed Publication Demonstrating Efficacy of its Neutralizing Antibody Therapeutic Against COVID-19
Read More →
OCT 20, 2020
Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for Treatment of COVID-19
Read More →
MAR 3, 2020
Abpro Forms Strategic Partnership to Advance Two Bispecific Antibody Candidates in Asian Markets
Read More →
FEB 28, 2019
Abpro and NJCTTQ Enter Into Partnership For Development of Multiple Novel Bispecific Antibodies
Read More →
NOV 29, 2016
Medimmune and Abpro Enter into A Collaborative Agreement For a Novel Bispecific Antibody
Read More →
OCT 13, 2016
GEN Roundup: Immunoassays: Life Science Critical Tools
Read More →
MAY 20, 2016
Abpro Announces Agreements with Two Boston Hospitals
Read More →
APR 25, 2016
Abpro Announces Investment and Partnership with Essex Bio
Read More →
OCT 10, 2014
Abpro Co-Founder Eugene Chan Wins Nokia Sensing XChallenge
Read More →


November 6, 2019
Abpro's TetraBi Platform for T-cell Engaging Antibodies targeting Claudin 18.2-expressing cancers Published for the 2019 SITC meeting
Read More →
MAY 16, 2019
Abpro's TetraBi Platform for T-cell Engaging Antibodies Published for the 2019 ASCO Meeting
Read More →
Back To Top